106
Participants
Start Date
November 11, 2024
Primary Completion Date
June 9, 2025
Study Completion Date
June 9, 2025
Flu Seasonal /SARS-CoV-2 mRNA Dose 1
A Flu mRNA vaccine composition in combination with Dose 1 of a COVID-19 component will be administered.
Flu Seasonal /SARS-CoV-2 mRNA Dose 2
A Flu mRNA vaccine composition in combination with Dose 2 of a COVID-19 component will be administered.
Flu Seasonal mRNA
An investigational mRNA Flu Seasonal vaccine will be administered.
SARS-CoV-2 mRNA Dose 1
Dose 1 of an investigational mRNA COVID-19 vaccine will be administered.
SARS-CoV-2 mRNA Dose 2
Dose 2 of an investigational mRNA COVID-19 vaccine will be administered.
Licensed Flu Seasonal
A licensed Flu Seasonal vaccine will be administered.
Licensed COVID-19 mRNA
A licensed mRNA COVID-19 vaccine will be administered.
Placebo
A placebo will be administered.
GSK Investigational Site, Rochester
GSK Investigational Site, Hialeah
GSK Investigational Site, Miami
GSK Investigational Site, Miami
GSK Investigational Site, Anniston
GSK Investigational Site, St Louis
GSK Investigational Site, Lenexa
GSK Investigational Site, Omaha
GSK Investigational Site, Rolling Hills Estates
Lead Sponsor
GlaxoSmithKline
INDUSTRY